Pharma BD Deal Intelligence
Teva / Cephalon: Partially Achieved (Score: 52/100)
Full analysis, sources & comparables →Teva acquired Cephalon for $6.8B, a specialty pharmaceutical company.
The FTC required Teva to sell rights to generic cancer pain drug and generic muscle relaxant as conditions of the $6.8 billion acquisition of Cephalon,…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Teva acquired Cephalon for $6.8B, a specialty pharmaceutical company.
Teva / Cephalon: Partially Achieved (Score: 52/100)
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Cephalon Inc. (this deal) | 2011 | $6.8B | 46 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
← Browse all deals · How we score deals
More: 2011 deals · Teva Pharmaceutical Industries Ltd. deals · Neurology deals